Infinity Pharmaceuticals, Inc. is a Cambridge, Massachusetts-based biopharmaceutical company focused on developing novel oncology therapeutics. Historically, the company developed drug programs targeting PI3K isoforms, including duvelisib and the experimental anti-tumor drug eganelisib. The company has conducted multiple clinical trials, including the MARIO-1, MARIO-275, and MARIO-3 studies. Infinity, which previously traded on the Nasdaq under the symbol INFI, operates through its wholly-owned subsidiary, Infinity Discovery, Inc.
